NovellusDx and Primetech Sign an Exclusive Dealer Agreement in JapanExclusive Dealer Agreement • August 31st, 2018
Contract Type FiledAugust 31st, 2018Tokyo, Japan and Jerusalem, Israel, September 3th , 2018 – NovellusDx, Ltd. (CEO: Haim Gil- Ad, headquarters: Jerusalem Bio-Park, Hadassah medical center, Ein-Kerem Campus, Israel) and Primetech Co., Ltd. (President: Ryosuke Ogihara, Head office: 1-3-25 Koishikawa, Bunkyo-ku, Tokyo, Japan) announce that Primetech will provide NovellusDx' functional genomics assay "FACT – Functional Annotation for Cancer Treatment" as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.